Oncocyte CORP DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Oncocyte Corporation has filed a definitive proxy statement with the SEC, signaling upcoming shareholder actions.
Oncocyte Corporation's 2025 Annual Meeting of Shareholders will be held virtually on June 27, 2025, to vote on director elections, accounting firm ratification, executive compensation, and an equity incentive plan amendment.
Oncocyte Corporation is asking shareholders to approve an amendment and restatement of its 2018 Equity Incentive Plan to increase the number of shares available for issuance and make other changes to the plan's administration.
Oncocyte Corporation will hold its 2024 Annual Meeting of Shareholders virtually on June 28, 2024, to vote on director elections, ratification of the accounting firm, and executive compensation.